Plain-English translation of NCT06852469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers are studying how lorazepam, a calming medication, affects the brain's ability to manage fear and arousal in veterans with PTSD. This is not a treatment trial — instead, the medication is being used as a research tool to help scientists identify which veterans might benefit most from new PTSD medications in the future. The study uses brain imaging and a special computer-based task to measure how the medication changes the brain's control over fear responses.
PTSD affects people very differently, and current treatments don't work equally well for everyone. Researchers believe that a specific subgroup of veterans — those with high levels of arousal and fear — might benefit from medications that work in a particular way on the brain's calming system. By understanding how this medication affects the brain, scientists hope to develop better, more targeted treatments for these veterans.
You likely qualify if…
You likely don't qualify if…
You would visit the research site twice, about one week apart. At one visit, you'll receive a single dose of lorazepam; at the other visit, you'll receive a placebo (inactive pill) — the order is chosen randomly. During each visit, you'll complete a computer-based task designed to measure how your brain controls fear responses, and researchers will use brain imaging to observe how the medication affects your brain activity. The entire study involves two sessions with a one-week break in between.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States